NeuroHealing Pharmaceuticals To Present At Rodman & Renshaw Techvest Seventh Annual Healthcare Conference, Nov. 8

For Immediate Release

NEWTON, Mass./EWORLDWIRE/Nov. 3, 2005 --- NeuroHealing Pharmaceuticals, Inc., a private company developing therapeutic products for individuals with chronic brain injuries, today announced that Neal M. Farber, Ph.D., CEO of NeuroHealing, is scheduled to present at the upcoming Rodman & Renshaw Techvest Seventh Annual Healthcare Conference. Dr. Farber will present information on NeuroHealing's three clinical stage programs. The presentation is currently scheduled for 4:35 p.m. (EST) on Tuesday, November 8, 2005. The event will be held at the New York Palace Hotel in New York.

The conference will feature presentations from more than 290 public and privately held emerging growth healthcare companies presenting data on an array of therapeutic topics. The event will unite companies with institutional investors, venture capitalists, senior corporate executives and experts from the scientific and medical communities. Details regarding the conference can be obtained at www.rodmanrenshaw.com.

About NeuroHealing

NeuroHealing is a clinical stage company developing novel therapeutics to improve the functional outcome of post-acute neurorehabilitation patients, including disorders such as traumatic brain injury, stroke, Parkinson's disease and other motor neuron diseases. NeuroHealing is developing reprofiled drug candidates, each with early evidence of clinical efficacy, extensive human safety data and featuring formulation and drug delivery strategies.

The company's lead product, NH001 is designed to accelerate the recovery and improve the functional outcome of patients from a coma, vegetative or minimally conscious state following a traumatic brain injury. NeuroHealing's second product to reach the clinic, NH004, is a novel treatment for sialorrhea (drooling or un-controlled salivation), a major and highly embarrassing complication of Parkinson's Disease and in many neurological conditions, including Cerebral Palsy and ALS. NeuroHealing's third product candidate, NH02D, is designed to improve the rehabilitation of patients who remain with chronic motor and cognitive disabilities following a stroke.

For more information, visit www.NeuroHealing.com.

   HTML: http://www.eworldwire.com/pressreleases/13033
   PDF: http://www.eworldwire.com/pdf/13033.pdf
   MOBILE: http://e4mobile.com/view_release.php?id=13033
   ONLINE NEWSROOM: http://www.eworldwire.com/newsroom/305366.htm
   NEWSROOM RSS FEED: http://newsroom.eworldwire.com/xml/newsrooms/305366.xml
   LOGO: http://www.eworldwire.com/newsroom/305366.htm

CONTACT:
Daniel Katzman
NeuroHealing Pharmaceuticals
Newton, MA
PHONE. 617.331.4111
EMAIL: info@neurohealing.com
http://www.neurohealing.com

SOURCE: NeuroHealing Pharmaceuticals